KBC Group NV Sells 56,764 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

KBC Group NV reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 93.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,750 shares of the company's stock after selling 56,764 shares during the period. KBC Group NV's holdings in CRISPR Therapeutics were worth $128,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in CRSP. Magnetar Financial LLC bought a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $359,000. Baker BROS. Advisors LP lifted its stake in shares of CRISPR Therapeutics by 55.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after acquiring an additional 464,936 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after acquiring an additional 10,579 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in CRISPR Therapeutics by 14.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock worth $1,334,000 after buying an additional 4,914 shares during the period. Finally, Green Alpha Advisors LLC boosted its stake in shares of CRISPR Therapeutics by 132.9% in the 1st quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock valued at $1,952,000 after purchasing an additional 32,732 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Down 3.7%

Shares of NASDAQ:CRSP traded down $2.20 during midday trading on Friday, hitting $56.80. 2,883,963 shares of the stock traded hands, compared to its average volume of 1,945,413. The stock has a market capitalization of $4.91 billion, a PE ratio of -12.57 and a beta of 1.82. The business's 50 day moving average is $42.15 and its two-hundred day moving average is $41.17. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $63.68.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same quarter in the previous year, the firm posted ($1.43) earnings per share. The firm's quarterly revenue was up 71.6% on a year-over-year basis. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the sale, the insider owned 6,068 shares of the company's stock, valued at $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on CRSP. Barclays cut their price target on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. Chardan Capital reiterated a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, June 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a report on Tuesday. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a report on Friday, May 16th. Finally, Piper Sandler reissued an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.